Literature DB >> 1388877

Osteomyelitis caused by Mycobacterium haemophilum: successful therapy in two patients with AIDS.

R L Yarrish1, W Shay, V J LaBombardi, M Meyerson, D K Miller, D Larone.   

Abstract

OBJECTIVE: Difficulties involved in diagnosis and response to antimicrobial therapy are described in detail for two cases of biopsy-proven osteomyelitis caused by Mycobacterium haemophilum in AIDS patients.
SETTING: Two large, private teaching hospitals in New York City, New York, USA. PATIENTS, PARTICIPANTS: A 31-year-old woman with previous diagnoses of candida esophagitis and peripheral neuropathy (patient 1), and a 37-year-old man with Kaposi's sarcoma (patient 2).
INTERVENTIONS: One patient was treated with a combination of rifampin, ethambutol, clofazimine, and ciprofloxacin, while the other received rifampin, ciprofloxacin and doxycycline. Both patients also received a short course of intravenous amikacin. MAIN OUTCOME MEASURES: Disease activity was monitored clinically by observing resolution of skin ulcers, lymphadenopathy, and pain and swelling in areas affected by osteomyelitis.
RESULTS: Both patients experienced complete resolution of signs and symptoms of M. haemophilum infection. Patient 1 was treated for 17 months and remains well after 10 months without therapy. Patient 2 shows no evidence of infection after 14 months of therapy.
CONCLUSIONS: M. haemophilum infection must be considered in the differential diagnosis of osteomyelitis in AIDS patients, although specialized culture techniques are required to isolate and identify this pathogen. Excellent clinical response can be achieved with oral antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1388877

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  11 in total

Review 1.  Epidemiology of infection by nontuberculous mycobacteria.

Authors:  J O Falkinham
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

Review 2.  Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans.

Authors:  M A Saubolle; T E Kiehn; M H White; M F Rudinsky; D Armstrong
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

Review 3.  Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections.

Authors:  Jerome A Lindeboom; Lesla E S Bruijnesteijn van Coppenraet; Dick van Soolingen; Jan M Prins; Eduard J Kuijper
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

Review 4.  Mycobacterium haemophilum: an emerging pathogen.

Authors:  T E Kiehn; M White
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

5.  Restriction fragment length polymorphism analysis of clinical isolates of Mycobacterium haemophilum.

Authors:  K Kikuchi; E M Bernard; T E Kiehn; D Armstrong; L W Riley
Journal:  J Clin Microbiol       Date:  1994-07       Impact factor: 5.948

Review 6.  CT/MRI of musculoskeletal complications of AIDS.

Authors:  S H Wyatt; E K Fishman
Journal:  Skeletal Radiol       Date:  1995-10       Impact factor: 2.199

7.  Activities of antimicrobial agents against clinical isolates of Mycobacterium haemophilum.

Authors:  E M Bernard; F F Edwards; T E Kiehn; S T Brown; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

8.  Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin.

Authors:  B A Atkinson; R Bocanegra; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

9.  A cluster of four cases of Mycobacterium haemophilum infection.

Authors:  T E Kiehn; M White; K J Pursell; N Boone; M Tsivitis; A E Brown; B Polsky; D Armstrong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-02       Impact factor: 3.267

10.  Atypical focal osteomyelitis as initial manifestation of AIDS.

Authors:  A Akiki; Y Bilde
Journal:  Case Rep Orthop       Date:  2011-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.